Ślusarczyk, A.; Bryant, H.E.; Chen, E.; Hitchcock, I.; Zeidler, M.; Chantry, A.; Thomas, S.
Preclinical Investigation of Inhibition of the DNA Damage Response as a Targetted Therapy in Myeloproliferative Neoplasms Shows Synergism of ATR Inhibitors with Standard-of-Care Treatment. Med. Sci. Forum 2021, 3, 17.
https://doi.org/10.3390/IECC2021-09209
AMA Style
Ślusarczyk A, Bryant HE, Chen E, Hitchcock I, Zeidler M, Chantry A, Thomas S.
Preclinical Investigation of Inhibition of the DNA Damage Response as a Targetted Therapy in Myeloproliferative Neoplasms Shows Synergism of ATR Inhibitors with Standard-of-Care Treatment. Medical Sciences Forum. 2021; 3(1):17.
https://doi.org/10.3390/IECC2021-09209
Chicago/Turabian Style
Ślusarczyk, Aleksander, Helen E. Bryant, Edwin Chen, Ian Hitchcock, Martin Zeidler, Andrew Chantry, and Sally Thomas.
2021. "Preclinical Investigation of Inhibition of the DNA Damage Response as a Targetted Therapy in Myeloproliferative Neoplasms Shows Synergism of ATR Inhibitors with Standard-of-Care Treatment" Medical Sciences Forum 3, no. 1: 17.
https://doi.org/10.3390/IECC2021-09209
APA Style
Ślusarczyk, A., Bryant, H. E., Chen, E., Hitchcock, I., Zeidler, M., Chantry, A., & Thomas, S.
(2021). Preclinical Investigation of Inhibition of the DNA Damage Response as a Targetted Therapy in Myeloproliferative Neoplasms Shows Synergism of ATR Inhibitors with Standard-of-Care Treatment. Medical Sciences Forum, 3(1), 17.
https://doi.org/10.3390/IECC2021-09209
